Komori
Daito Pharmaceutical (4577) · InitiativeRestated

Adoption of the Fair Value Measurement Standard

First written in FY2022-Q1. 2 of 3 entries say "Restated". Latest entry: FY2022-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY2022-Q32021: 120212022: 22022
Same theme, other companies
Preparing for adoption of accounting standards for fair value measurementA theme 1870 companies write about · 5 as a headwind · 3 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1911 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3RestatedAnnual report

    「The Accounting Standard for Fair Value Measurement (ASBJ Statement No. 30, 4 July 2019; hereinafter, the “Fair Value Measurement Standard”) and other related standards were applied from the beginning of the first quarter, and, in accordance with the transitional treatment prescribed in paragraph 19 of the Fair Value Measurement Standard and paragraph 44-2 of the Accounting Standard for Financial Instruments (ASBJ Statement No. 10, 4 July 2019), the new accounting policies prescribed by the Fair Value Measurement Standard and other related standards have been applied prospectively. There is no impact on the quarterly consolidated financial statements.」

    The Group continues to explain the application of the fair value measurement standards and that there was no impact on the quarterly consolidated financial statements.
  2. FY2022-Q2RestatedAnnual report

    「The Accounting Standard for Fair Value Measurement (ASBJ Statement No. 30, 4 July 2019; hereinafter, the “Fair Value Measurement Standard”) and other related standards were applied from the beginning of the first quarter, and, in accordance with the transitional treatment prescribed in paragraph 19 of the Fair Value Measurement Standard and paragraph 44-2 of the Accounting Standard for Financial Instruments (ASBJ Statement No. 10, 4 July 2019), the new accounting policies prescribed by the Fair Value Measurement Standard and other related standards have been applied prospectively. There is no impact on the quarterly consolidated financial statements.」

    The Group continued its application of the Fair Value Measurement Standard and other standards and explained that there was no impact on the financial statements.
  3. FY2022-Q1First statedAnnual report

    「The Company applied the Accounting Standard for Fair Value Measurement (ASBJ Statement No. 30, 4 July 2019; hereinafter, the "Fair Value Measurement Accounting Standard") and other standards from the beginning of the first quarter of the current consolidated fiscal year. In accordance with the transitional treatment prescribed in Paragraph 19 of the Fair Value Measurement Accounting Standard and Paragraph 44-2 of the Accounting Standard for Financial Instruments (ASBJ Statement No. 10, 4 July 2019), the Company will apply the new accounting policies prescribed by the Fair Value Measurement Accounting Standard and other standards prospectively. This has had no impact on the quarterly consolidated financial statements.」

    The Accounting Standard for Fair Value Measurement and other related standards were applied from the beginning of the first quarter of the current fiscal year, and this is the first disclosure of the policy to apply the new accounting policies on a prospective basis. The Company explains that there was no impact on the financial statements.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Adoption of the Fair Value Measurement Standard | Daito Pharmaceutical Co.,Ltd. (4577) | Komori